CAS: 2095849-04-8

CSF1R-IN-1 is a small molecule inhibitor, which is derived from synthetic chemical processes designed to selectively target the colony-stimulating factor 1 receptor (CSF1R) tyrosine kinase. The primary mode of action of CSF1R-IN-1 involves the inhibition of the CSF1R signaling pathway. This pathway is crucial for the regulation of the development and function of macrophages, which are vital for immune response and homeostasis. By selectively binding to the ATP-binding site of CSF1R, CSF1R-IN-1 effectively blocks the receptor's activity, thus reducing unwanted macrophage-mediated inflammation and proliferation. CSF1R-IN-1 is employed in various research applications, primarily focused on the study of macrophage biology and related pathologies, including cancer, inflammatory diseases, and bone disorders. It is utilized in in vitro and in vivo models to elucidate the role of CSF1R in disease mechanisms and to explore potential therapeutic interventions aimed at modulating macrophage activity. As a research tool, CSF1R-IN-1 provides valuable insights into the therapeutic potential of CSF1R inhibition in conditions characterized by aberrant macrophage activity.

CSF1R-IN-1 is a CSF1R inhibitor with IC50 of 0.5 nM.

5-(1-Methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)nicotinamide

CSF1R-IN-1